Related Experiment Video
Updated: Sep 13, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Association Between Atherogenic Index of Plasma and Clinical Outcomes in Peritoneal Dialysis Population
Jiayao Lan1,2, Chunyan Yi1, Ruihua Liu1,2
1Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 58th Zhongshan Road II, Guangzhou 510080, China.
Insights
The atherogenic index of plasma (AIP) is a significant predictor of adverse outcomes in peritoneal dialysis (PD) patients. Higher AIP levels correlate with increased risks of mortality and peritonitis, aiding clinical management.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biochemistry
Background:
- The atherogenic index of plasma (AIP) is a marker for cardiovascular disease risk.
- Its prognostic value in peritoneal dialysis (PD) patients requires further investigation.
- Understanding AIP's role is crucial for managing PD patient outcomes.
Purpose of the Study:
- To investigate the association between baseline AIP levels and clinical outcomes in PD patients.
- To determine the relationship between AIP and all-cause mortality, cardiovascular mortality, and peritonitis risk.
- To assess AIP's utility as a predictive marker in this population.
Main Methods:
- Retrospective cohort study of incident PD patients (2006-2021).
- Stratification of patients based on baseline AIP levels.
- Kaplan-Meier curves, Cox regression, and subgroup analyses were employed.
Main Results:
- Higher baseline AIP levels were significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and peritonitis.
- Continuous AIP levels demonstrated a positive correlation with mortality and peritonitis risk, even after covariate adjustment.
- The study included 2460 participants with an average age of 45.9 years.
Conclusions:
- The atherogenic index of plasma (AIP) serves as a valuable predictive marker for adverse outcomes in PD patients.
- AIP can potentially enhance risk stratification and guide clinical management strategies.
- Further research can explore interventions targeting AIP to improve PD patient prognosis.
Abstract:
Background: The atherogenic index of plasma (AIP), a prognostic indicator for cardiovascular disease, has not been fully explored in relation to clinical outcomes in patients receiving peritoneal dialysis. This study aims to elucidate the relationship between baseline AIP levels and all-cause mortality, cardiovascular mortality, and the peritonitis risk in this population. Methods: This retrospective cohort study included incident peritoneal dialysis patients in our center from 1 January 2006 through 31 December 2021. The end of the follow-up time was 31 December 2023. The participants were stratified by baseline AIP levels. Kaplan-Meier curves, Cox regression analyses, and subgroup analyses were used to evaluate associations with clinical outcomes. Results: The average age of the 2460 participants in this study was 45.9 years, and 1456 (59.2%) of them were men. Diabetic nephropathy (19.5%) was the second most common kidney disease, after primary glomerulonephritis (60.8%). The higher AIP tertile group was significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and peritonitis compared to the lowest AIP group, as evidenced by the Kaplan-Meier curves and the multivariate analyses. Continuous AIP levels also showed a positive correlation with the all-cause mortality and peritonitis risk, even after controlling for covariates. Conclusions: Our study highlights AIP as a predictive marker for adverse outcomes in PD patients, emphasizing its potential utility in risk stratification and clinical management.
More Related Videos
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis I: Introduction and Procedure
Chronic Kidney Disease III: Interprofessional Care
Peripheral Artery Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations

